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vomiting. She had been diagnosed with HIV infection 10 
weeks earlier and had a CD4+ T-cell count of 54 
cells/mm3. Six weeks prior to her current presentation, 
a diagnosis of pulmonary MDR-TB was made, and she 
was initiated on treatment that included terizidone 750 
mg/d, ethionamide 750 mg/d, ofloxacin 800 mg/d, 
ethambutol 1000 mg/d and kanamycin 1000 mg/d 
intramuscularly (IM). Other medications included the 
anti-retroviral drugs stavudine, lamivudine and efavirenz. 
She had no other medical conditions and was not using 
any other chronic medication such as diuretics, or any 
over-the-counter drugs. 
On clinical examination she was hypotensive and thought 
to have extracellular fluid (ECF) volume contraction. She 
was severely wasted and had proximal muscle weak-
ness. Chest examination revealed tachypnoea and 
bilateral crackles. 
Laboratory results on admission (Table 1) revealed severe 
metabolic alkalosis, hypokalaemia, hyponatraemia, hypo-
calcaemia, hypomagnesaemia and hypophosphataemia. 
 
ABstrAct
Multidrug-resistant Mycobacterium tuberculosis infection (MDR-TB) is a highly prevalent communicable disease 
in South Africa and often occurs in those with HIV infection. We describe three HIV-infected patients with pul-
monary MDR-TB who received treatment with a regimen that included kanamycin and subsequently developed a 
Bartter-like syndrome. The clinical presentation varied from asymptomatic to severely symptomatic electrolyte 
disturbances, with one fatal outcome. This report highlights the importance of the routine monitoring of electrolytes 
in MDR-TB patients receiving treatment that includes kanamycin. 
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BAcKGrOUND
This article describes three cases of Bartter-like syndrome 
caused by kanamycin, an aminoglycoside used for the 
treatment of multidrug-resistant Mycobacterium tuber-
culosis infection (MDR-TB). Bartter syndrome is a renal 
disease characterised by an inability of the thick ascending 
limb of the loop of Henle (TALH) to reabsorb salt and 
was first described by Dr F Bartter in 1962 [1]. Con-
sequently, a group of autosomal recessive disorders with 
the common characteristic of renal salt wasting together 
with hypokalaemia and metabolic alkalosis was des-
cribed [2]. Other Bartter-like syndrome phenotypes 
with similar biochemical abnormalities but without pri-
mary renal disease have also been described in cystic 
fibrosis [3], surreptitious diuretic use [4] and as a com-
plication of the use of chemotherapeutic agents [5].
cAsE 1
A 36-year-old female presented with a history of acute 
worsening of chronic diarrhoea, severe weakness, weight 
loss and a seizure. She denied having any episodes of 
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Blood glucose concentrations were normal. Urine chem-
istry revealed marked sodium and potassium wasting. 
Subsequent blood tests revealed acute kidney injury.
A clinical diagnosis of acute-on-chronic gastroenteritis was 
made, and she was admitted to hospital and initiated on 
intravenous isotonic fluids with replacement of her electro-
lytes. The acute kidney injury was ascribed to acute tubular 
necrosis (ATN) resulting from the hypovolaemia and the 
exposure to the nephrotoxic agent, kanamycin. 
The combination of the metabolic alkalosis, hypokalaemia 
and renal wasting of sodium and potassium in the setting of 
ECF volume contraction led us to diagnose a Bartter-like 
syndrome, most likely also a result of kanamycin exposure.
This antibiotic was stopped on day 6. The patient’s gastro-
enteritis responded well to treatment and her electro- 
lytes gradually improved, but the respiratory symptoms 
worsened, and she eventually died. 
cAsE 2
A 20-year-old female presented with a 2-week history of 
constitutional symptoms, diarrhoea and abdominal cramps, 
without any vomiting. She received symptomatic treatment 
and was discharged to her local clinic for follow-up of 
laboratory results. There she was notified that she had 
tested positive for HIV-infection (CD4+ T-cell count was 
531 cells/mm3) and pulmonary MDR-TB. She was started 
on MDR-TB treatment that included terizidone 750 mg/d, 
ethionamide 750 mg/d, ofloxacin 800 mg/d, ethambutol 
1000 mg/d and kanamycin 1000 mg/d IM, and anti-retroviral 
therapy which included tenofovir, lamivudine and efavirenz.
Fourteen weeks later she was readmitted, this time com-
plaining of muscle cramps and lethargy. On examination 
she was not acutely ill, was normotensive and had a positive 
Chvostek sign. Laboratory tests revealed metabolic alka-
losis, hyponatraemia, hypokalaemia, hypocalcaemia, hypo-
magnesaemia and hypophosphataemia (Table 1). The 
patient was admitted for electrolyte replacement and 
cardiac monitoring.
As the differential diagnosis included Fanconi syndrome 
secondary to tenofovir, this agent was replaced with 
zidovudine. However, the presence of metabolic alkalosis 
made the diagnosis of a proximal tubular lesion unlikely. 
Urine chemistry revealed wasting of potassium, phosphate 
and magnesium (Table 1). A diagnosis of Bartter-like syn-
drome secondary to kanamycin was made and the drug 
was stopped without substitution. Her condition improved 
after oral and IV electrolyte replacement with resolution of 
her muscle cramps and weakness and no further complaints. 
cAsE 3
A 36-year-old female known with HIV (CD4+ T-cell count 
of 16 cells/mm3) presented with a history of anorexia, 
weight loss and night sweats. A diagnosis of pulmonary 
MDR-TB was made, and she was started on moxifloxacin 
400 mg/d, ethambutol 800 mg/d, teridizone 750 mg/d, 
pyrazinamide 1 g/d, isoniazid 300 mg/d (KatG gene mutation 
was negative), pyridoxine 25 mg/d and kanamycin 1000 
mg/d IM. She was also known to suffer from major 
depression that was being treated with fluoxetine 20 mg/d. 
She did not use diuretics. Three months following the 
initiation of MDR-TB treatment, owing to virological fail-
ure, she was started on second-line anti-retroviral therapy 
that included ritonavir-boosted liponavir, abacavir and 
lamivudine. Two months later, she developed Clostridium 
difficile-associated diarrhoea without any vomiting. The 
clinical examination did not indicate obvious ECF volume 
contraction. Laboratory tests revealed hyponatraemia, 
hypokalaemia, hypocalcaemia and hypophosphataemia 
(Table 1). Urine tests revealed potassium, magnesium and 
phosphate wasting, as well as hypocalciuria.
Bartter-like syndrome was diagnosed, and the kanamycin 
was stopped without substitution. She received oral and 
intravenous electrolyte replacement and was treated for 
the pseudomembranous colitis with metronidazole, and 
later vancomycin. She responded to the treatment and was 
discharged to her local TB clinic for continuation of therapy.
DIscUssION
Aminoglycosides are well known for their nephrotoxicity 
and commonly cause ATN, but may also cause renal tubu-
lar dysfunction that may manifest as Fanconi syndrome, 
distal renal tubular acidosis and Bartter-like syndrome [6]. 
Bartter-like syndrome secondary to aminoglycosides is an 
uncommon occurrence. Aminoglycosides that have been 
implicated in causing this syndrome include gentamicin [7], 
amikacin [8], tobramycin [7] and netilmicin [9]. 
There is variability in nephrotoxicity for different types of 
aminoglycosides. The most nephrotoxic of the amino-
glycosides is neomycin followed by gentamicin, with 
streptomycin the least nephrotoxic [10]. Kanamycin has 
intermediate toxicity. This variability is partly related to the 
cationic charge that is generated by the number of amine 
groups attached to the drug [11]. 
Bartter syndrome may be inherited or acquired. In the case 
of aminoglycosides, it is thought to be a result of stimula-
tion of the calcium-sensing receptor (CaSR) that is located 
on the basolateral surface of principal cells lining the thick 
ascending limb of the loop of Henle [12]. The CaSR is a 
unique cell surface receptor which does not have a single 
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ligand but can be stimulated by numerous polyvalent 
cationic compounds, including aminoglycoside antibiotics. 
Stimulation of this receptor closes the rat outer medulla 
potassium (ROMK) channel located at the luminal sur- 
face, preventing potassium recycling. This has two effects: 
(1) the sodium–potassium-2 chloride cotransporter (NKCC) 
ceases to function, and (2) loss of the lumen-positive 
charge prevents the normal paracellular reabsorption of 
sodium, magnesium and calcium (Figures 1A and 1B). The 
hypophosphataemia which was present in our cases may 
have been a consequence of malnutrition and/or renal 
losses due to a partial Fanconi’s syndrome and/or high 
tubular flow due to the diuretic effect of kanamycin.  
The South African guidelines for the treatment of MDR- 
TB ranks aminoglycosides as the preferred bactericidal 
injectable antibiotic and recommends 4–6 months of 
therapy during the intensive phase of treatment [13]. An 
interesting finding in our cases is that the route of admini-
stration for kanamycin was intramuscular. The other case 
reports for aminoglycoside-induced Bartter-like syndrome 
reported intravenous routes of administration. 
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table 1.  Blood and urine chemistry results. the values for the urine parameters should be compared to the expected (appropriate) 
renal responses in the setting of non-renal causes for the ecF volume contraction and the serum chemistry abnormalities seen in 
our patients.
reference range case 1 case 2 case 3
Serum 
Sodium mmol/L 135–147 115 134 128
Potassium mmol/L 3.3–5.3 2.1 1.8 2.4
Chloride mmol/L 101–109 – – 91
Urea mmol/L 2.6–7.0 4.0 3.0 3.7
Creatinine µmol/L 49–90 158 148 60
Calcium mmol/L 2.05–2.56 1.63 1.7 1.83
Magnesium mmol/L 0.65–1.10 0.33 0.46 0.31




Sodium mmol/L < 20 96 49 55
FENa % < 1% 8.8 – 0.5
Potassium mmol/L – 23.5 15.1 26.8
K/creatinine ratio mmol/mmol < 1.5 15.7 – 4.7
Chloride mmol/L – 106 – 116
Urea mmol/L – 32 – 117
Creatinine mmol/L – 1.5 – 5.7
Calcium mmol/L – – – 1.58
Ca/creatinine ratio mmol/mmol – – – 0.28
Magnesium mmol/L – – 4.2 1.85
FEMg % < 2% – – 6.28
Phosphate mmol/L – – 8.5 3.35
FEP % < 5% – – 5.78
Osmolality mosm/kgH2O 50–1200 274 – –
Venous blood gas
pH 7.36–7.44 7.58 7.56 7.34
HCO3 mmol/L 23–27 36.8 37.0 26
Abbreviations: FE, fractional excretion.
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With South Africa having one of the highest burdens of 
MDR-TB in the world, the use of aminoglycosides for this 
indication is expected to continue [14]. Newer drugs, such 
as bedaqualine [15], are now becoming available as part 
of the armamentarium for the treatment of MDR-TB and 
may replace aminoglycosides in the future, reducing the 
risk of this dangerous treatment-related complication.     
cONcLUsIONs
To the best of our knowledge, these three cases represent 
a first description of kanamycin-induced Bartter-like syn-
drome. Asymptomatic MDR-TB patients who are receiving 
treatment that includes an aminoglycoside should be 
screened routinely for electrolyte disorders, and those 
presenting with muscle weakness and lethargy should be 
investigated for the possibility of aminoglycoside-induced 
Bartter-like syndrome. 
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figure 1. electrolyte reabsorption in the thick ascending 
limb of the loop of Henle. 
1a: (1) entry of sodium, potassium and chloride into the 
principal cell through the na–K–cl cotransporter (nKcc, 
in green) with recycling of potassium through the rat outer 
medulla-K (rOMK) channel (red). (2) the recycling of K 
induces a lumen-positive charge that (3) facilitates the 
paracellular reabsorption of cations. 
1b: (4) a cationic ligand (blue) binding to the calcium-sensing 
receptor (yellow) results in the closure of rOMK (5). the 
inhibition of K recycling and (6) the loss of the lumen-
positive charge causes reduced transport through nKcc 
as well as via the paracellular route with subsequent urinary 
excretion of cations and anions. 
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